Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of intravenous efgartigimod in generalized myasthenia gravis
jRCT2080224994Phase 3Completed
- Sponsor
- argenx
- Start
- Dec 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Efgartigimod with Placebo (2 arms). Started Dec 2019; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2080224994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224994.